Call us at (888) 828-2206. We'll help answer any questions you may have.
AO-176 is an anti-CD47 monoclonal antibody currently being developed for patients with multiple myeloma and select solid tumors. Arch Oncology is evaluating this therapy both as a monotherapy and in combination with standard therapies.
February 07, 2022
December 07, 2020
SparkCures is working closely with Arch Oncology to provide the most up-to-date information on this treatment. Use the button above to add this treatment to your list of favorites.
Learn more about how we work with industry partners
You can give us a call at (888) 828-2206 or create your account to add this treatment to your list of favorites. We'll send you alerts when this treatment is updated.
Create My Account